SCHEMBL4338431

SCHEMBL4338431

CC1=NN(c2cccc(F)c2)C(=O)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.70
KMT2A Q03164 7/20 0.70
KDM4E B2RXH2 5/20 0.70
GAA P10253 4/20 0.70
ALDH1A1 P00352 6/20 0.66
MEN1 O00255 6/20 0.66
TDP1 Q9NUW8 4/20 0.66
CYP1A2 P05177 1/20 0.66
CHRM2 P08172 1/20 0.66
CYP3A4 P08684 1/20 0.66
CHRM1 P11229 1/20 0.66
TSHR P16473 1/20 0.66
PTGS1 P23219 1/20 0.66
DRD3 P35462 1/20 0.66
SMN1; SMN2 Q16637 1/20 0.66
APP P05067 7/20 0.65
CA1 P00915 1/20 0.62
CA2 P00918 1/20 0.62
CA9 Q16790 1/20 0.62
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12756285 0.89 MAPT (0.81) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL125079 0.84 MAPT (0.74) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL29096030 0.83 MAPT (0.59) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL1260486 0.83 MAPT (1.00) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL1854311 0.81 MAPT (0.70) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL11858486 0.81 KMT2A (0.70) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL4662959 0.81 MAPT (0.70) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL4661641 0.81 MAPT (0.65) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL3529446 0.80 MAPT (0.70) MAPTKMT2AKDM4EGAAALDH1A1
SCHEMBL31420004 0.80 MAPT (0.70) MAPTKMT2AKDM4EGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130078213-A1 THROMBOPOIETIN MIMETICS GLAXOSMITHKLINE LLC 2013-03-28 US disclosed
EP-1889838-B1 Thrombopoietin mimetics SMITHKLINE BEECHAM CORP (US) 2009-10-14 EP disclosed
EP-1889838-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2008-02-20 EP disclosed
EP-1864981-A1 Thrombopoietin mimetics SmithKline Beecham Corporation (US) 2007-12-12 EP disclosed
US-20070129338-A1 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION 2007-06-07 US disclosed
US-20040019190-A1 Thrombopoietin mimetics NOVARTIS AG (CH) 2004-01-29 US disclosed
EP-1294378-A4 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORP (US) 2004-01-28 EP disclosed
EP-1294378-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2003-03-26 EP disclosed
WO-2001089457-A2 THROMBOPOIETIN MIMETICS SMITHKLINE BEECHAM CORPORATION (US) 2001-11-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129338-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885KMT2A 1838/4885KDM4E 3202/4885
US-20130078213-A1 THROMBOPOIETIN MIMETICS MPL, THPO, TEK MAPT 4627/4885KMT2A 1838/4885KDM4E 3202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.